Vimian Group Reports Strong Q1 2026 Momentum With Revenue Growth, Solid Cash Flow, and Two Acquisitions

Vimian Group AB opened 2026 with a positive first quarter, reporting higher revenue, strong organic growth, improved profit, and continued expansion across its global animal health platform. The Stockholm-based company said revenue increased by 8% to EUR 116.0 million in Q1 2026, compared with EUR 107.5 million in the same period last year. Organic growth reached 9%, showing that the business grew mainly through stronger underlying demand rather than only through acquisitions.

Key Financial Highlights

Adjusted EBITA rose 3% to EUR 29.2 million, compared with EUR 28.3 million a year earlier. The adjusted EBITA margin was 25.2%, slightly lower than 26.3% last year, as Vimian continued investing in MedTech orthopedics and new market entries in Veterinary Services.

Operating profit also improved clearly, rising to EUR 21.2 million from EUR 15.6 million. Profit for the period increased to EUR 10.1 million, compared with EUR 4.7 million in Q1 2025. Earnings per share before and after dilution were EUR 0.02, compared with EUR 0.01 last year.

Strong Organic Growth Across Core Segments

According to the company’s earnings call, three of Vimian’s four business segments — Specialty Pharma, Veterinary Services, and Diagnostics — delivered double-digit growth during the quarter. CEO Alireza Tajbakhsh said this performance was ahead of the broader global animal health market and reflected positive customer sentiment from veterinarians and industry partners.

Cash Flow Remains Healthy

Vimian also reported solid operational cash generation. Cash flow from operating activities reached EUR 23.0 million in Q1 2026, up from EUR 17.1 million in the same quarter last year. This stronger cash flow gives the company more flexibility to support growth investments, acquisitions, and long-term business development.

Two Acquisitions Add Growth Potential

During the quarter, Vimian completed two acquisitions: I-Vet, an Italian diagnostics company, and Favna, an innovative Danish clinic group. Together, the two businesses are expected to add around EUR 10 million in annual revenue to the group.

Management’s View

CEO Alireza Tajbakhsh described the quarter as a strong start to the year, supported by positive momentum across the group. He noted that Vimian’s growth was driven by both market demand and continued execution in its operating segments. The company also emphasized that investments in MedTech orthopedics and Veterinary Services are part of its longer-term plan to expand in attractive animal health niches.

Company Background

Vimian is a global animal health company active in four key areas: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. The company is headquartered in Stockholm, Sweden, operates in more than 80 markets, employs about 1,300 people, and generated annual revenue of approximately EUR 425 million before the latest quarter.

Outlook

The Q1 2026 results suggest that Vimian entered the year with stable demand, strong organic growth, and a clear acquisition strategy. While margins were slightly lower due to growth investments, the company’s higher revenue, improved operating profit, and stronger cash flow point to a resilient business model in the animal health industry.

Overall, Vimian’s first-quarter performance shows a company still focused on profitable growth, international expansion, and specialized animal healthcare solutions.

#VimianGroup #AnimalHealth #Q12026Earnings #VeterinaryBusiness #SlimScan #GrowthStocks #CANSLIM